NCT06424626View on ClinicalTrials.gov

A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
MelanomaMucosal MelanomaMetastatic Melanoma
Interventions
DRUG

AK104+Axitinib

Subjects receive AK104 10mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.

DRUG

AK112+Axitinib

Subjects receive AK112 20mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER